Bicara Therapeutics, Inc. (BCAX)
22.02
-0.62
(-2.74%)
USD |
NASDAQ |
Sep 21, 16:00
22.02
0.00 (0.00%)
After-Hours: 20:00
Bicara Therapeutics Total Liabilities (Quarterly) : 43.48M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 43.48M |
| March 31, 2026 | 39.64M |
| December 31, 2025 | 127.84M |
| September 30, 2025 | 21.91M |
| June 30, 2025 | 18.39M |
| March 31, 2025 | 19.12M |
| Date | Value |
|---|---|
| December 31, 2024 | 77.32M |
| September 30, 2024 | 14.62M |
| June 30, 2024 | 16.28M |
| March 31, 2024 | |
| December 31, 2023 | 15.47M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.873M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 512.24M |
| Shareholders Equity (Quarterly) | 468.77M |
| Debt to Equity Ratio | 0.0025 |
| Current Ratio | 11.59 |
| Net Debt Paydown Yield | -0.01% |